Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/14—Decongestants or antiallergics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals

Definitions

• the present invention relates to a stable aqueous solution containing oxymetazoline and / or xylometazoline, a zinc salt and a buffering salt.
• the aqueous solution is particularly suitable for local administration to the nose for mucosal swelling.
• Oxymetazoline [6-tert-butyl-3- (4,5-dihydro-1-H-imidzol-2-ylmethyl) -2,4-dimethylphenol] and xylometazoline [2- (4-tert-butyl-2,6- dimethylbenzyl) -4,5-dihydro-1-H-imidazole] are vasoconstrictor acting imidazole ⁇ -sympathomimetics, which are preferably used locally for mucosal swelling in the nose. In particular, aqueous solutions are used.
• oxymetazoline and xylometazoline are unstable.
• hydrochloride salts oxymetazoline and xylometazoline are more stable in aqueous solution, but it also occurs in these storage, in particular at elevated temperature, to an undesirable hydrolytic degradation of the active ingredients, in particular by hydrolytic cleavage of Imidazolrings.
• a nonaqueous solvent for example oils or organic solvents.
• oils have a comparatively higher viscosity and a poorer wettability of hydrophilic surfaces, which precludes a nasal application of a fine distribution of the active substance contained on the nasal mucosa.
• Organic solvents are usually not toxicologically harmless and / or cause irritation of the nasal mucosa.
• non-aqueous formulations due to their viscosity or potential interactions with packaging and dosage systems, especially those made of plastics, are less suitable for developing drug solutions. This is especially true for plastic spray bottles, which are widely used in rhinology.
• the hydrolytic degradation should be reduced due to cleavage of the imidazoline ring.
• a stable aqueous solution containing oxymetazoline and / or xylometazoline can be obtained if it contains a zinc salt and a buffer salt in addition to the oxymetazoline and / or xylometazoline.
• the present invention therefore provides an aqueous solution containing at least oxymetazoline and / or xylometazoline, a zinc salt and a buffering salt.
• An aqueous solution according to the invention is when at least part of the solvent contained consists of water.
• Solvent components may contain all solvents which are suitable for nasal application, in particular alcohols such. As ethanol, propanol, propanediol or glycerol.
• the aqueous solution contains as solvent water or ethanol-water mixtures, more preferably the solvent consists of water.
• oxymetazoline and / or xylometazoline is preferably in the form of one of its pharmaceutically acceptable salts such.
• B. as hydrochloride or as nitrate.
• Oxymetazoline and / or xylometazoline are each particularly preferably contained as the hydrochloride.
• quantities of oxymetazoline or xylometazoline are included in the present patent application, these relate in each case to the corresponding hydrochloride salts.
• Other salt forms of oxymetazoline or xylometazoline nitrate are used in an equimolar amount corresponding to the respective hydrochloride salt.
• zinc salt all pharmaceutically acceptable zinc salts can be used according to the invention.
• zinc chloride, zinc lactate, zinc sulfate, Zinkeitrat, zinc acetate, zinc histidine, Zinkorotat, zinc aspartate and / or zinc gluconate are included.
• Zinc gluconate is particularly preferred as the zinc salt.
• Buffer salts in the context of the present invention are the salts of weak acids with strong bases or weak bases with strong acids, which completely dissociate in aqueous solution and form a buffer system in the presence of the respective salt-forming acid or base.
• Buffer salts which can be used according to the invention are, for example, alkali metal salts, in particular the sodium and / or potassium salts, of pharmaceutically usable weak organic or inorganic acids, such as.
• acetic acid or Citric acid or boric acid Particular preference is given to sodium citrate as buffering salt.
• the aqueous solution further contains a pharmaceutically acceptable acid or base.
• acid or base it is possible to include all pharmaceutically acceptable acids or bases which do not lead to any incompatibilities with the other constituents of the aqueous solution according to the invention.
• the preferred acid is the respective acid forming the buffer salt, d. H. the acid form of the anion contained in the buffering salt, or as the base the base forming the buffering salt, d. H. the base form of the cation contained in the buffering salt.
• the aqueous solution according to the invention in addition to the buffer salt sodium citrate citric acid, d. H. the acid form of citrate ions contained in the buffering salt as an anion, or NaOH, d. H. the base form of the sodium ion contained in the buffering salt as cation.
• aqueous solution according to the invention can be applied for nasal administration in all dosage forms suitable for nasal administration, such as, for example, nose drops or nasal sprays, by means of suitable dosing devices, such as bottles with a dropping device or nasal spray pumps.
• the aqueous solution has a pH of pH 4 to pH 7.5, preferably a pH of pH 5.0 to pH 7.2, more preferably a pH of about pH 6 , 0 on.
• the exact adjustment of the pH can be effected by adding the acid or base corresponding to the buffer salt and / or by adding another physiologically acceptable acid or base.
• the desired pH of a sodium citrate-containing solution by adding the acid form of the anion contained in the buffer salt, ie by the addition of citric acid or by Addition of the base form of the cation contained in the buffer salt, ie by addition of NaOH and / or by addition of another acid or base, in particular by addition of hydrochloric acid or sodium hydroxide, can be adjusted.
• Isotonicity is present at an osmolality of about 280 mOsm. Adjustment of osmolality may be accomplished by varying the amounts of solutes present in the aqueous solution in addition to oxymetazoline and / or xylometazoline, i. H.
• an isotonizing agent preferably a physiologically acceptable salt, such as sodium or potassium chloride, or a physiologically acceptable polyol, such as a sugar alcohol, in particular sorbitol or glycerol, in the Isotonization required concentration.
• an isotonizing agent preferably a physiologically acceptable salt, such as sodium or potassium chloride, or a physiologically acceptable polyol, such as a sugar alcohol, in particular sorbitol or glycerol, in the Isotonization required concentration.
• a physiologically acceptable salt such as sodium or potassium chloride
• a physiologically acceptable polyol such as a sugar alcohol, in particular sorbitol or glycerol
• the aqueous solution of the invention contains oxymetazoline and / or xylometazoline in a concentration of 0.005 wt .-% to 1.0 wt.%.
• oxymetazoline and / or xylometazoline in a concentration of 0.01 wt .-% to 0.5 wt.%, Most preferably in a concentration of between 0.05 wt .-% to 0.1 wt .-% ,
• the aqueous solution of the invention contains that the zinc salt in a proportion of 0.1 wt .-% to 10 wt .-%.
• the zinc salt is preferably present in a proportion of 1.8-6.0% by weight.
• the buffer salt is contained in an amount of 0.01% by weight to 3.0% by weight.
• the buffer salt is preferably contained in a proportion of 0.2-1.5% by weight.
• the aqueous solution according to the invention contains 0.005% by weight to 0.1% by weight of oxymetazoline hydrochloride or xylometazoline hydrochloride, 1% by weight to 10% by weight of zinc gluconate and 0.5% by weight to 5% by weight.
• % Citrate and has a pH of about 6.
• the aqueous solution contains only one of the active ingredients oxymetazoline and xylometazoline in the form of its hydrochloride salt.
• Example 2 Water for injections is presented. The weighed substances are added in portions with stirring and dissolved. The finished solution is filtered through a 0.2 micron sterile filter 'and filled into the appropriate containers.
• Example 2
• the aqueous solution is prepared analogously to Example 1.
• Citric acid 2.140 g
• the aqueous solution is prepared analogously to Example 1.
• Citric acid 8.480 g
• Example 5 The aqueous solution is prepared analogously to Example 1.
• Example 5 The aqueous solution is prepared analogously to Example 1.
• the aqueous solution is prepared analogously to Example 1.
• Citric acid 1 441 g
• the aqueous solution is prepared analogously to Example 1,
• the aqueous solution is prepared analogously to Example 1.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Otolaryngology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Ophthalmology & Optometry (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34201503

Family Applications (1)

Country Status (19)

Cited By (5)

Families Citing this family (11)

Citations (2)

Family Cites Families (6)

• 2003
  • 2003-08-13 DE DE10337186A patent/DE10337186A1/de not_active Withdrawn
• 2004
  • 2004-07-14 BR BRPI0413478-8A patent/BRPI0413478A/pt not_active IP Right Cessation
  • 2004-07-14 WO PCT/EP2004/007780 patent/WO2005018601A1/de not_active Ceased
  • 2004-07-14 US US10/567,845 patent/US20060222718A1/en not_active Abandoned
  • 2004-07-14 DE DE502004003305T patent/DE502004003305D1/de not_active Expired - Lifetime
  • 2004-07-14 EP EP04740995A patent/EP1663141B1/de not_active Expired - Lifetime
  • 2004-07-14 JP JP2006522915A patent/JP4750703B2/ja not_active Expired - Fee Related
  • 2004-07-14 DK DK04740995T patent/DK1663141T3/da active
  • 2004-07-14 AT AT04740995T patent/ATE357212T1/de active
  • 2004-07-14 MX MXPA06001596A patent/MXPA06001596A/es active IP Right Grant
  • 2004-07-14 CA CA2535533A patent/CA2535533C/en not_active Expired - Fee Related
  • 2004-07-14 KR KR1020067002872A patent/KR20060065677A/ko not_active Ceased
  • 2004-07-14 ES ES04740995T patent/ES2282871T3/es not_active Expired - Lifetime
  • 2004-07-14 CN CNB2004800227931A patent/CN100531733C/zh not_active Expired - Fee Related
  • 2004-07-14 AU AU2004266443A patent/AU2004266443A1/en not_active Abandoned
  • 2004-07-14 RU RU2006107446/15A patent/RU2343918C2/ru not_active IP Right Cessation
  • 2004-07-14 PT PT04740995T patent/PT1663141E/pt unknown
  • 2004-07-14 PL PL04740995T patent/PL1663141T3/pl unknown
• 2006
  • 2006-03-10 ZA ZA200602071A patent/ZA200602071B/en unknown
• 2007
  • 2007-05-21 CY CY20071100685T patent/CY1107633T1/el unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events